echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Up to $110 million!

    Up to $110 million!

    • Last Update: 2022-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 13, LENZ Therapeutics (hereinafter referred to as LENZ) and Keixing Pharmaceutical announced that the two parties have signed an exclusive license for the development and commercialization of the drugs LNZ100 and LNZ101 developed by the former for the treatment of presbyopia in Greater China.


    Presbyopia (also known as presbyopia) is a progressive and irreversible decline in the eye's ability to focus on near objects due to the hardening of the lens in the eye with age


    Acetylcridine is a small-molecule acetylcholinesterase receptor agonist that causes pupillary miosis, resulting in a pinhole effect that improves near vision


    A clinical trial completed by LENZ showed that acetylcridine maintained optimal pin pupil size ranging from 1.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.